pHLIP is an abbreviation of pH (low) insertion peptide, meaning a peptide that is incorporated into the cell membrane under conditions of reduced pH. The name describes a peptide platform that utilizes acid-dependent interactions with cell membranes. Unlike the conventional drug name that identifies a single finished medicinal product, pHLIP can refer to a family of peptide sequences and constructs containing imaging agents or therapeutic payloads. Understanding which specific construct has been tested is fundamental to interpreting the results.[1][2]
Available evidence includes detailed experiments on cell membranes, studies of the delivery of substances to cells, imaging and treatment studies in animals, and clinical studies of selected conjugates. These levels of evidence should be distinguished. Demonstrating the incorporation of the peptide into the membrane is not equivalent to confirming an improvement in the survival of cancer patients. Similarly, a clinical study of a single conjugate does not confirm the efficacy of all products based on pHLIP.
What is pHLIP? Names, synonyms and identity
The most important terminological distinction is the difference between the technological platform and the specific experimental substance.
The platform describes a design strategy that can be adapted to different applications. On the other hand, a specific construct represents a specific combination of a peptide, chemical modifications, and any attached functional components.
When the publication uses the term pHLIP in the introduction, it may discuss the overall strategy. However, if it presents tissue bioavailability, distribution or toxicity, the results should be interpreted in relation to the precisely studied construct.
Distinguishing helps to analyze publications from different fields of science as well.
Biophysical studies may concern the incorporation of the peptide into model membranes, while oncological publications may focus on fluorescent or cytotoxic conjugation.
The common name unites these projects, but it does not eliminate differences in endpoints, material preparation, or clinical significance.
A systematic review should identify these differences before combining or comparing the results.
The way the name is written helps distinguish pHLIP from other materials sensitive to pH.
Many polymers, nanoparticles, and drugs react to changes in acidity, but this property alone does not make them pHLIP constructs.
This particular research line includes peptide sequences analyzed for their incorporation into membranes at low pH.
Scientific claims should refer to these studies, and not to the technology for delivering substances sensitive to acidity at all.
The abbreviation is written as pHLIP, With distinction the pH component.
Terms also appear in the publications pH low-insertion peptide, pH (low) insertion peptide and the plural number pHLIPs.
These terms describe related peptides that interact with membranes, rather than a single universally standardized formulation.[2][3]
The basic concept is the conditional incorporation of the peptide into the membrane.
In well-studied systems, the peptide can exist in an aqueous solution, bind to the surface of the membrane, and then integrate into it in the form of a helix when conditions favor such a transition.
The three-state model is a useful description, however its course depends on the sequence, the composition of the membrane, and the experimental conditions.[3]
Names like pHLIP ICG i CBX-12 they identify more specific constructs or development programs.
pHLIP ICG combines a peptide with a fluorescent dye – indocyanine green.
CBX-12 contains a peptide that forms a bond with the membrane at low pH, a chemical linker, and an anti-tumor charge in the form of exetane.
These names should not be treated as synonyms for the unglycosylated pHLIP peptide.[4][5]
Therefore, a valuable description of the study should identify the peptide variant, the charge, the linker, the formulation, and the intended use.
The very name of the family is not sufficient to compare activity, exposure, and safety.
How is pHLIP classified? Peptide, protein, mixture, or other substance?
A useful classification separates the molecular composition from the intended use.
The unglycosylated pHLIP sequence is a peptide.
The Koniugat pHLIP with a dye is a molecular construct designed for imaging.
Koniugat pHLIP with a cytotoxic load is, however, a therapeutic candidate.
These categories may share a component that interacts with the membrane, but require different assessments of pharmacokinetics, safety, and efficacy.
It should also not be assumed that the peptide delivering the substance acts in the same way as an antibody or a ligand that recognizes a specific receptor.
The lesion may contain heterogeneous areas with different extracellular conditions.
The proposed selectivity depends on these local conditions and the ability of the construct to reach the tissue.
This changes the requirements for validation. Researchers must measure where the construct is assembled and whether the signal or the delivered load exhibits sufficient selectivity for the intended application.
The peptide-based carrier does not have to be an approved drug.
The experimental conjugate is also not a substitute for an isolated carrier.
Regulatory classification refers to the complete product and its intended use.
Consequently, a clinical study of one combination does not mean that the entire family has a defined clinical indication.
The individual sequences of pHLIP are peptides.
A specific synthetic sequence can be an exactly defined molecule, but the name of the family includes many projects.
Therefore, classifying all studies on pHLIP as studies on a single substance is incorrect.[2]
Koniugat pHLIP is a more complex molecular structure.
Its peptide portion can influence the targeting to specific tissues or the delivery of substances, while the attached dye, drug, or other cargo performs a separate function.
For example, in CBX-12 the pharmacologically active compound is exetecane.
The subject of the clinical study is the complete conjuagate, not the free peptide itself.[5]
The term „targeting peptide” also requires clarification.
In the case of pHLIP, targeting is based primarily on the physicochemical properties of the tissue environment and its interaction with the membrane, rather than necessarily binding to a receptor specific to the tumor.
It should not be confused with a universal sequence that recognizes cancer cells.
Being classified as a peptide also does not mean that it has a mild biological effect.
The peptide delivering the substance can be combined with a highly cytotoxic load.
The safety profile of the resulting structure must be evaluated as a whole.
The chemical category, intended function, and clinical risk are separate issues.
The structure and composition of pHLIP – what has been established?
The three-state model is particularly helpful in interpreting experiments describing the binding of a peptide to the membrane.
The peptide can first contact the membrane, then bind to its surface, and only under favorable conditions can it enter a deeper embedding state.
These are conceptually different observations.
The technique for detecting the presence of lipids does not necessarily itself distinguish the surface-bound peptide from the bilayer-pass peptide.
Comparisons of structure and function require taking into account the exact experimental framework.
Lipid composition, load, temperature, and local acidity can alter the energy balance between states.
Therefore, the embedding profile measured in the artificial bilayer is a valuable mechanistic result, but it does not constitute a universal numerical threshold for human tumors.
Delivery to tissues is additionally dependent on blood supply, extracellular transport, elimination, and membrane availability.
The conjugation introduces further structural issues.
The fluorescent dye can change the hydrophobicity or distribution.
The cytotoxic drug can affect the size of the molecule and its toxicity.
The split link creates a separate issue of load release.
The characteristics should therefore confirm the identity and integrity of the complete conjugate, and not just the peptide sequence.
If charge release is assumed, experiments should distinguish the intact construct from the released substance and identify the conditions under which the dissociation occurs.
A concise but complete description of the scientific identity should include the peptide variant, modification of the ends and side chains, the joining site, the linker chemistry, the charge, and the formulation.
These are not just production details.
They define what the biological results actually are.
The studies confirmed conformational changes associated with the membranes for the analyzed pHLIP sequences.
The most well-known model involves an unorganized or less-ordered state in solution or on the surface of the membrane, and an alpha-helical state passing through the lipid bilayer under conditions favorable for incorporation.
This is a mechanistic model supported by biophysical experiments, and not a claim that every variant behaves identically.[3][6]
Sequence modifications can alter behavior during incorporation, kinetics, and delivery of the substance.
A 2018 study compared multiple constructs, including combined peptide complexes and variants containing modified residue sequences or non-standard amino acids.
Researchers measured behavior in membranes, cellular effects, and targeting of tumors, rather than assuming that a common family name guarantees equivalent properties.[2]
The chemistry of the load and the connection introduces another level of variability.
The attachment site can influence whether the cargo is presented outside the cell or transported through the membrane.
Some experimental constructs utilize disulfide binding designed to enable release into a reducing intracellular environment.
Such a property must be demonstrated for a specific construct.
It is not a universal mechanism for releasing all the conjugates of pHLIP. [1]
For this reason, the article does not provide a single sequence or mass of molecules as a definition of the entire platform.
The report enabling the replication of the experiment should identify the actual sequence, final modifications, loading, linker, and analytical characteristics of the material under study.
Studies on pHLIP – evidence in humans, animals and in the laboratory
It is best to analyze the evidence as separate research questions, rather than as a continuous process of confirming clinical benefits.
The first question concerns whether a specific sequence exhibits the predicted behavior in the membrane.
Second – whether it can deliver or locate the attached cargo within cells or tissues.
Third – whether the complete construct provides a significant imaging or therapeutic outcome in animals.
The final question concerns whether properly designed studies demonstrate acceptable efficacy and safety in humans.
Success at one stage justifies moving on to the next, but it cannot replace it.
The terminology of the research is important here.
Experiment in vitro in the membrane it can provide detailed kinetic or energetic information while remaining remote from clinical conditions.
Imaging studies in mice can include circulation and distribution within the tumor, but they still differ from human anatomy and diseases.
A feasibility study or an early-stage study in humans may show that the product can be administered and evaluated without having a statistical design that would confirm an improvement in survival or operational outcomes.
Laboratory tests
Laboratory studies are particularly informative for pHLIP, because the proposed mechanism is essentially of a biophysical nature.
Researchers can modify the pH, lipid composition, and charge properties by monitoring the structure of the peptide or the signals associated with the membrane.
Such control helps verify whether the acidity changes behavior in accordance with predictions and whether the observed charge signal is consistent with incorporation or delivery.
At the same time, the laboratory result should be described taking into account the limitations of the test.
Fluorescence associated with cells can result from surface binding, internalization, or released dye, depending on the system.
The reduction in cell viability may reflect the activity of the charge without confirming its selectivity towards the tumor.
The strongest mechanistic interpretation uses complementary methods to distinguish these possibilities, rather than relying on a single measurement.
Early primary studies showed that acidity-dependent incorporation into the membrane and the delivery of the attached molecules to the cells occurred.
Further work characterized the binding energy of the membrane and folding, and analyzed the effect of changes in charge properties on delivery.
These experiments support a credible transport mechanism while also demonstrating the importance of charge chemistry.[1][6][7]
The cellular experiment demonstrating the delivery of a substance or the reduction of viability is not the result of clinical treatment.
It usually does not take into account circulation, elimination, tissue heterogeneity, and competing exposures occurring throughout the body.
The proper interpretation therefore separates the evidence from the molecular process from the confirmation of the therapeutic selective efficacy.
Animal studies and translational research
Imaging in animals allows us to analyze questions that purified membrane experiments cannot answer.
They concern whether the conjugate maintains stability in circulation, reaches the target tissue, remains detectable, and generates a background signal in other places.
These are key issues for transferring the results to clinical practice.
A strong response to acidity in a controlled two-layer system does not necessarily provide useful contrast in a living organism.
In fluorescence-assisted surgery, it is also necessary to distinguish between the quality of the imaging and the effectiveness of the procedure.
Contrast, signal-to-background ratio, and detection depth can support the development of technology.
However, the clinical benefit would require evidence that image information correctly changes decisions and improves important treatment outcomes.
The cited studies do not justify replacing such later results with imaging parameters alone.
The 2020 pHLIP ICG study analyzed the effect on membranes, pharmacology, toxicology, bioavailability, and imaging in preclinical systems.
Clinical-relevant imaging equipment was used, but the use of such equipment does not make the experiment a clinical trial in humans.
The study supports the development of a specific fluorescent conjugate towards clinical applications, but does not confirm the benefits for patients across all pHLIP projects.[4]
A subsequent preclinical publication analyzed the pHLIP ICG imaging in the short-wave infrared range.
The improvement in image contrast or detectability in the mouse model provides valuable technical and biological evidence.
However, in itself it does not confirm better surgical margins, fewer reoperations, or improved survival in humans.[8]
Clinical trials in humans
Clinical studies are an important stage that goes beyond the preclinical confirmation of a concept.
However, early-stage projects often focus on safety, feasibility, dose characterization, or initial activity.
The goal of the study should be read from the protocol and the entry in the registry, rather than being claimed solely based on the presence of oncology patients.
The specified endpoint is a planned measurement, not evidence that it has been achieved.
In the case of pHLIP ICG, the clinical question primarily concerns the imaging construct under specific surgical conditions.
In the case of CBX-12, a complete drug conjugate containing a potent anti-tumor agent is being studied in patients with advanced malignant tumors.
These programs are not competing versions of the same intervention.
Their threats and endpoints should not be combined.
The status in the registry can also change regardless of the publication history.
The completed study may have unpublished or incomplete results.
The update to the registry may not contain the details necessary for interpreting efficacy or adverse events.
A careful review notes the status and date, and then separately evaluates the available full results.
The National Cancer Institute lists a Phase I/IIa study evaluating pHLIP ICG in breast imaging and surgery.
The study description confirms that the construct has entered clinical trials.
However, the declared goals should not be presented as achieved results. [9]
CBX-12 has also undergone clinical evaluation with the first administration in humans.
The ClinicalTrials.gov registry for NCT04902872 it describes an open-label Phase I/II study in patients with advanced or metastatic, treatment-resistant solid tumors.
According to the update from August 2026, the study was considered completed.
The entry specifies the presence of an integrase peptide that forms a membrane at low pH, a self-degrading linker, and exacatecan.
The completion status itself does not confirm efficacy, approval, or a favorable comparison with standard treatment.[5]
Clinical activity means that it would be incorrect to conclude that all studies related to pHLIP are limited to cells and animals.
It would also be incorrect to treat the start of clinical trials as confirmation of the entire platform for any disease.
Mechanisms of action analyzed in pHLIP studies
The attractiveness of the pHLIP mechanism lies in the fact that extracellular acidity can serve as a signaling molecule without the need for the expression of a specific surface receptor.
This is an interesting research strategy, but it does not mean that all tumors have the same acidity or that healthy tissues always have an indifferent pH.
A significant variable is the local environment with which the specific construct interacts, rather than the mean pH attributed to the entire organ or tumor.
Protonation and incorporation into the membrane are related steps of the proposed model.
However, the final functional effect depends on the component that is included.
A decoy image can be useful when it remains localized and emits a detectable signal.
The therapeutic construct may require an appropriate release process and sufficient intracellular exposure to the cargo.
The best design for one application does not have to be the best for another.
Mechanistic claims also require appropriate controls.
Comparing different acidity conditions can help confirm sensitivity to pH.
Comparison of the pHLIP conjugate with corresponding unconjugated or unincorporating controls may help identify the contribution of the peptide.
Measurements of binding to the membrane, translocation, cargo release, and biological responses should be treated as separate stages of the causal chain.
The main mechanism involves the association of changes in the peptide’s properties that are dependent on acidity with its incorporation into the membrane.
The protonation of groups capable of ionization can increase the energy efficiency of incorporation into the lipid environment.
The resulting passage depends on the sequence and the surrounding membrane.
Therefore, there is no single pH value that defines the behavior of all pHLIP constructs in all tissues.[6]
The three-state model distinguishes the state in solution, binding to the surface, and intracellular incorporation.
This is important because the mere detection of the peptide near the membrane does not prove that it passed through it or delivered the charge to the cytoplasm.
Experiments must distinguish between surface binding and the incorporation and release of charge.[3]
The transport of cargo also has physical limitations.
Size, polarity, hydrophobicity, the way of attachment and the energy associated with the incorporation can influence the possibility of delivering a specific molecule.
A study showing effective transport of one compound does not confirm unlimited transport of all medications.
Studies that modify the properties of the charge directly illustrate this limitation.[7]
Acidosis itself is not a characteristic unique to tumors.
Early work discussed several pathological conditions in which extracellular acidity may be of importance.
Therefore, the proposed mechanism of targeting acidity should be evaluated in conjunction with bioavailability and exposure in non-malignant tissues.
„Targeting the tumor” should describe the measured selectivity, and not suggest complete exclusivity towards the tumor.[1]
Limitations of scientific evidence regarding pHLIP
One of the limitations is the difficulty in generalizing the results from controlled conditions of acidity to complex human tissues.
Local pH changes spatially and temporally, and not every area of the disease progression is equally accessible.
Tissue perfusion, extracellular matrix, necrosis, and elimination can all influence the observed accumulation.
The construct may work well in one model of the tumor, showing a different distribution in the next one.
The measurement method also affects the interpretation.
The imaging intensity depends on the optical properties of the tissue and the imaging system, and not solely on the amount of the present conjugate.
Similarly, the ratio of the tumor signal to the background is not identical with diagnostic sensitivity, surgical accuracy, or patient benefit.
The research should identify the measurement method and the endpoint that is actually supported by the result.
Safety cannot be generalized based on the peptide backbone alone, in a conjugate containing a strong drug.
Interchange, cargo, distribution outside the intended destination and products of decomposition can pose significant risks.
Even in the case of designs depicting tolerance and elimination, a complete formulation needs to be evaluated.
Early clinical exposure provides information, but does not allow the rare or delayed adverse events to be reliably ruled out.
There is also a limitation related to publication and reporting.
Mechanistic experiments are often presented in great detail, whereas clinical programs may initially only be visible in registries and conference abstracts.
Inconsistent reporting can create the impression of a continuous chain of evidence, even though key data on clinical outcomes is still not available.
A responsible article should present these gaps, rather than fill them with likely extrapolations.
The biggest interpretational problem is treating the platform as a single drug.
Sequencing variants, connectors, loading, imaging methods, and disease contexts differ.
A result for one construct may suggest a hypothesis for another, but it does not confirm identical delivery, safety, or efficacy.
Experimental endpoints should also be separated.
In situ embedding, accumulation of fluorescence, cell death, tumor reduction, surgical visualization, and survival are different outcomes.
Each one requires its own methods and controls.
Strong evidence regarding the early stage of delivery cannot fill the gaps in later clinical outcomes.
The heterogeneity of tumors creates additional difficulties.
Acidity and availability can vary within and between changes.
Rotation and elimination affect the amount of structure reaching the target.
A favorable average imaging signal may mask areas of poor delivery or uptake beyond the intended tissue.
The imaging agent and therapeutic conjugate have different issues regarding the balance of benefits and risks.
The imaging must demonstrate a useful diagnostic or therapeutic efficacy.
A cytotoxic coneugate must, however, demonstrate that the benefits of the treatment outweigh the toxicity.
The results of one application should not be used as a general statement of safety for the other.
Research priorities and unresolved questions
Further development of research on pHLIP would benefit from standardized reporting of sequence identity, charge chemistry, integration conditions, and complete formulation.
Studies using different designs should not be compared solely based on the most visible imaging or response values.
A common set of clearly defined measurements would facilitate understanding of which modifications improve the delivery and which merely change the experimental context.
In applications that address important questions, these include the relationship between measured fluorescence and the actual distribution of malignant tissue, efficacy in different types of lesions, and the consequences of false signals.
The studies should describe the way in which the images are interpreted, the use of blinding where possible, and the verification of the results using appropriate reference methods.
Technical image quality and real clinical usefulness should remain separate outcomes.
In therapeutic applications, researchers must determine whether the targeting and release design improves the balance between tumor exposure and toxicity.
A strong charge can exhibit biological activity even without optimal targeting.
A well-designed comparison is necessary to determine the additional contribution of the pHLIP element.
Long-term safety, metabolism, and differences between patient populations are further questions that cannot be resolved solely through membrane studies.
Independent replication of results and transparent reporting are essential in both areas.
Negative or mixed results can also be informative, especially when the construct operates in one acid-base range or tissue model, but not in another.
The goal is not to consider the platform universally effective or ineffective.
It is about determining where certain projects work reliably, and where their limitations remain significant.
Frequently asked questions about pHLIP
1. Does pHLIP mean one defined substance?
No. pHLIP usually refers to a family of related peptides and structures that deliver substances.
The individual sequence or coniguate can be precisely defined, but the collective name does not specify the complete material.
A reliable assessment of the evidence therefore begins with the identification of the variant, the load, the link, and the formulation.[2]
For example, a free peptide assay cannot automatically characterize the distribution of the variant associated with the dye.
Even when the peptide fragment is similar, changes in the bond and charge can alter the behavior of the entire material.
Scientific indexing should therefore identify the exact construct, rather than grouping all results under one indistinguishable substance.
2. What do the available studies on pHLIP confirm?
They confirm the membrane-dependent behavior of the studied sequences and support applications related to the delivery of substances and imaging in experimental systems.
Selected combinations have also entered clinical trials in humans.
These results do not confirm the universal selectivity towards tumors or the clinical efficacy of all members of the family.[3][9]
The most convincing evidence concerns the experimentally observed membrane process.
The imaging and treatment results are at further stages and must be independently confirmed.
Clinical programs show progress towards human trials, but the scope of the findings still depends on the study design and the reported results.
3. What does the abbreviation pHLIP mean?
It means pH (low) insertion peptide, that is, a peptide that is incorporated into the membrane at low pH.
The name reflects the relationship between acidity and incorporation into the membrane.
It should be understood as a description of the research platform, and not a guarantee that every construct will be built at the same pH or maintain identical properties.[1]
The abstract describes a research family oriented towards the mechanism.
It does not specify a specific amino acid sequence, the loading charge, or the regulatory status.
Using the full name for the first appearance, followed by the identifier of the construct, improves the clarity of comparisons between publications.
4. Is pHLIP itself an anti-cancer drug?
Not as a general category.
Some devices are designed for imaging, while others contain therapeutic agents responsible for anti-cancer action.
Before assigning medicinal properties, the identity and function of the complete construct must be determined.[4][5]
The free peptide that delivers the substance and the conjugate containing the drug can have fundamentally different effects.
In therapeutic design, the antitumor load and the conditions for its delivery are key elements of the intervention.
The article should not imply that the carrier substance itself produced the clinical effect attributed to the complete preparation.
5. Is pHLIP a ligand of the tumor receptor?
Its basic mechanism involves a reaction with the membrane dependent on acidity, rather than the need to recognize a specific tumor receptor.
The distinction can broaden research possibilities, but it also means that acidity outside the tumors is important.
Selectivity therefore requires direct measurement, rather than inference based solely on the term „directional.”.
Distinction determines the appropriate controls.
The receptor-targeted substance can be studied for receptor binding.
The pHLIP project, on the other hand, requires evidence of membrane integrity that is sensitive to acidity and of selective distribution.
Both strategies may have limitations in heterogeneous tissues, but the proposed molecular recognition processes are different.
6. Does an acidic environment only occur in tumors?
No. Acidic extracellular environment can also occur in other pathological conditions.
This creates potential applications beyond oncology, but limits claims of total specificity for tumors.
The useful mechanism of targeting still needs to be evaluated in terms of distribution and effects in other tissues.[1]
Acidic conditions can accompany processes other than cancer.
Therefore, any declaration of preferential accumulation in the gut requires evaluation with respect to the corresponding healthy and disease-altered tissues.
The scientific question concerns the degree of selectivity achieved by the actual construct, and not whether acidity occurs exclusively in tumors.
7. Does pHLIP always enter the cytoplasm?
No. The binding to the membrane, the incorporation into it, and the translocation of the cargo are separate events.
Some designs may present the cargo on the outside of the cell, while others have it delivered to the inside.
Simply showing cell-associated fluorescence does not determine which process occurred.[1]
To confirm intracellular delivery, researchers need methods that distinguish the membrane-bound signal from material that has actually been transported into the interior.
In the case of designs designed to release a load, additional release measurement may be necessary.
These stages should not be inferred solely from fluorescence.
8. Can pHLIP deliver any molecule?
No. The chemistry of the cargo and the design of the structure affect the transport.
Experiments modifying the hydrophobicity of the charge show that the delivery is not independent of the properties of the attached molecule.
A successful example supports a specific project, but does not confirm the unrestricted transport of all medicines or macro-molecules. [7]
The properties of the cargo can change the energy of the membrane and transport.
Therefore, an effective experiment to deliver a small molecule cannot confirm the transport of a completely different cargo without further research.
When assessing feasibility, the attached molecule, linker, and release design must be taken into account.
9. Is pHLIP ICG the same as ordinary indocyanine green?
No. pHLIP ICG is a conjugate containing a peptide and the indocyanine green dye.
The addition of a targeting component can change the distribution and duration of the substance's action.
Therefore, evidence regarding the unconjugated dye does not automatically confirm the properties of the conjugate.
Its imaging effectiveness and safety require a construction-specific evaluation.[4]
The attached peptide can change the location of the dye accumulation and the time it remains in place.
That is why the coniguate must be evaluated separately regarding imaging quality and tolerance.
The approval or knowledge of a free dye in a given application does not in itself confirm the properties of the conjugate.
10. What is CBX-12?
CBX-12 is a conjugate of a peptide and a drug containing a peptide that forms a bond in the membrane at low pH, a self-degrading linker, and exetacene.
Clinical studies evaluate the complete construct.
It should not be described simply as a replaceable pHLIP vial or as evidence that an unopened pHLIP treats tumors.[5]
CBX-12 is an example of incorporating the pHLIP strategy into a more complex therapeutic project.
Its clinical results, when fully available, will relate to a specific combination of the peptide, the linker and the cargo and to a specific patient population.
They will not confirm the effectiveness of any construct based on pHLIP.
11. Does a completed clinical trial mean that the treatment is effective?
No. Completion is the administrative status of the study.
It does not inform whether final points were reached, how large the effects were, or whether the benefits outweighed the risks.
Therefore, the completed registration entry for CBX-12 should be distinguished from the full evaluation of the published results. [5]
The register can indicate the end of the recruitment process and the observation procedures, without presenting complete analyses.
Credible conclusions require real data, including the number of participants, uncertainties in estimates, adverse events, and definitions of endpoints.
Completion should be treated as a stage of the study, not a positive verdict regarding effectiveness.
12. Does tumor fluorescence indicate the destruction of tumor cells?
No. Fluorescence measures the imaging signal, not the therapeutic death of cells.
The signal can come from the tumor cells, surrounding tissue, circulation, or other compartments, depending on the design and the measurement time.
Therapeutic efficacy requires separate endpoints and appropriate controls.
The imaging signal can help locate the tissue without measuring whether the cancer cells have been destroyed.
Even a strong signal associated with a tumor can reflect distribution in many tissue compartments.
Demonstrating anti-tumor activity requires appropriate therapeutic testing and separate biological or clinical endpoints.
13. Do better images in mice indicate improved surgical outcomes in humans?
No. The improvement in pre-clinical imaging is an indirect result.
Clinical trials must assess whether the information accurately changes surgical decisions and improves important treatment outcomes.
Better contrast in an animal experiment provides a justification for further research, not evidence of improved surgery in humans.[8]
Imaging mice can identify promising technical properties under controlled conditions.
Surgical application in humans involves other depths of tissue, the distribution of disease, and the procedures and consequences of false positive or false negative signals.
A clinical trial must examine whether the technique improves decisions or outcomes under these conditions.
14. Can one pHLIP sequence confirm the properties of another?
Not without comparative evidence.
Changes in the sequence can affect membrane incorporation and biological distribution.
The load and the method of connection introduce further differences.
Family resemblance supports mechanistic hypotheses, but the properties of each intended construct require experimental confirmation.[2]
The change of a few residues can modify the peptide's interaction with the membrane and its behavior at different levels of acidity.
The added medicine or dye introduces additional differences.
Direct comparative studies are needed before assigning one construct to another for kinetic, distributional, or safety results.
15. Does the pHLIP conjugation have a universal built-in pH threshold?
No. The transition depends on the sequence and the surrounding conditions.
The composition of the membrane, the local environment, and the measurement method can all influence the observed behavior.
Therefore, the reported pH values for one laboratory system should not be presented as a universal clinical switch. [6]
The measured transformation associated with incorporation depends on the experimental system and the peptide variant.
Tissue environments are also heterogeneous and not fixed at a single pH value.
Presenting one laboratory value as a universal switch of action would have exaggerated the precision of the mechanism.
16. Does peptide-based delivery guarantee safety?
No. Safety depends on the complete structure, exposure, distribution, and load.
The peptide delivering the substance, combined with the cytotoxic agent, must be evaluated as the specific conjugate, and not solely on the basis of the term „peptide”.
Preclinical tolerance also does not allow for the determination of all the risks in humans.
A complete conjugate can contain substances with their own toxicological profiles, including potent anti-cancer agents.
The safety assessment must take into account the distribution of the structure, the way it breaks down and the resulting exposures.
Neither peptide chemistry nor favorable laboratory tolerance replace the evidence of safety in humans.
17. What is the most accurate short description of pHLIP?
pHLIP is a family of peptides that are incorporated into membranes in a pH-dependent manner and are used in studies of targeted drug delivery and imaging.
Some specific conjugates have reached the clinical evaluation stage, while many applications remain preclinical.
This description covers both the established concept of the platform and the need to present evidence specific to each structure.[2][9]
A concise summary should also indicate the level of evidence: the biophysical mechanism, delivery to cells, imaging in animals, or clinical studies in humans.
This prevents the erroneous reading of the word „targeted” as evidence of perfect specificity or established benefits for patients.
Applications
The most useful way to interpret PHLIP studies is to ask three questions for each claim: which peptide or conjugate was tested, what result was measured, and under which experimental or clinical conditions?
These questions prevent confusion regarding the outcome of incorporating the tumor treatment result into the membrane or the imaging signal with an improvement in survival.
Future progress will depend on specific constructs-specific comparisons, reproducible measurements of tissue selectivity, detailed assessment of pharmacokinetics and safety, and well-reported clinical trials tailored to the intended use.
The existing evidence provides strong justification for further research, while leaving important questions about clinical utility and the possibility of generalizing the results.
pHLIP can best be understood as a substance delivery platform comprising multiple sequences and conjugates.
The studies provided significant mechanistic evidence and enabled the initiation of clinical trials of selected products.
Conclusions regarding efficacy, specificity, and safety must remain linked to the exact design, application, and level of evidence.
Educational, medical and regulatory reservations
The article is of a scientific and educational nature and serves to interpret available research. It does not constitute medical advice, oncological diagnosis, treatment recommendations, or instructions for the preparation, dosage, administration, or procurement of experimental peptides and conjugates. Decisions regarding imaging, surgery, anti-cancer therapy, and participation in clinical trials require consultation with qualified medical personnel and appropriate supervision.
pHLIP describes a family of peptide drugs, not a single universally approved drug. Clinical studies of selected constructs do not confirm the approval, safety, or efficacy of other variants, dosages, formulations, or uses. The risk of a complete conjugate can significantly differ from the risk of an unconjugated peptide, especially when it contains a cytotoxic substance. The current regulatory status should be checked for the specific product and country.
References
- Reshetnyak, Y. K., Andreev, O. A., Lehnert, U., & Engelman, D. M. (2006). Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix. Proceedings of the National Academy of Sciences of the United States of America, 103(17), 6460–6465. https://doi.org/10.1073/pnas.0601463103
- Wyatt, L. C., Moshnikova, A., Crawford, T., Engelman, D. M., Andreev, O. A., & Reshetnyak, Y. K. (2018). Peptides of the pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors. Proceedings of the National Academy of Sciences of the United States of America, 115(12), E2811–E2818. https://doi.org/10.1073/pnas.1715350115
- Reshetnyak, Y. K., Segala, M., Andreev, O. A., & Engelman, D. M. (2007). A monomeric membrane peptide that lives in three worlds: in solution, attached to, and inserted across lipid bilayers. Biophysical journal, 93(7), 2363–2372. https://doi.org/10.1529/biophysj.107.109967
- Crawford, T., Moshnikova, A., Roles, S., Weerakkody, D., DuPont, M., Carter, L. M., Shen, J., Engelman, D. M., Lewis, J. S., Andreev, O. A., & Reshetnyak, Y. K. (2020). pHLIP ICG for delineation of tumors and blood flow during fluorescence-guided surgery. Scientific reports, 10(1), 18356. https://doi.org/10.1038/s41598-020-75443-5
- Cybrexa Therapeutics. (2026, August 20). Study of CBX-12 in subjects with advanced or metastatic refractory solid tumors (NCT04902872) [Clinical trial registry record]. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04902872
- Reshetnyak, Y. K., Andreev, O. A., Segala, M., Markin, V. S., & Engelman, D. M. (2008). Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer membrane. Proceedings of the National Academy of Sciences of the United States of America, 105(40), 15340–15345. https://doi.org/10.1073/pnas.0804746105
- Wijesinghe, D., Engelman, D. M., Andreev, O. A., & Reshetnyak, Y. K. (2011). Tuning a polar molecule for selective cytoplasmic delivery by a pH (Low) insertion peptide. Biochemistry, 50(47), 10215–10222. https://doi.org/10.1021/bi2009773
- Mc Larney, B. E., Kim, M., Roberts, S., Skubal, M., Hsu, H. T., Ogirala, A., Pratt, E. C., Pillarsetty, N. V. K., Heller, D. A., Lewis, J. S., & Grimm, J. (2023). Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green. Journal of Nuclear Medicine, 64(10), 1647–1653. https://doi.org/10.2967/jnumed.123.265686
- National Cancer Institute. (n.d.). Investigational scans (multiparametric MRI and pHLIP® ICG NIRF) for breast cancer imaging in patients undergoing surgery (NCI-2021-13268; NCT05130801). Retrieved October 26, 2026. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-13268